At a glance
- Originator Fujisawa
- Class Anti-inflammatories; Antirheumatics; Pyridines; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 15 Nov 1996 New profile
- 15 Nov 1996 Preclinical development for Rheumatoid arthritis in Japan (Unknown route)